- > About Us
- > CSR (Corporate Social Responsibility)
- > CSR Activities News
- > Daiichi Sankyo Announces Funding for 2nd-Term Activities of the Global Health Innovative Technology Fund
Daiichi Sankyo Announces Funding for 2nd-Term Activities of the Global Health Innovative Technology Fund
Daiichi Sankyo announced that it has committed to supporting the Global Health Innovative Technology Fund (GHIT Fund),*1 a public-private partnership originating in Japan to promote the creation of drugs for addressing infectious diseases in developing countries, during the second term of its activities (to be conducted over the five-year period from fiscal 2018 to fiscal 2022).
During the first term of the GHIT Fund's activities (from fiscal 2013 to fiscal 2017), Daiichi Sankyo participated by utilizing its compound library (consisting of small molecules and natural substances) in a screening program for exploring candidate compounds to treat tuberculosis, malaria, and neglected tropical diseases (NTDs), namely leishmaniasis and Chagas disease. Through this program, we have moved on to the lead optimization stage for malaria and the lead identification stage for tuberculosis and leishmaniasis / Chagas disease. We are currently advancing joint development together with prominent global research institutions,*2 and the unique technologies of all parties are being utilized in this undertaking.
Daiichi Sankyo CEO George Nakayama provided a statement on the Company's thoughts and initiatives with regard to the activities of the GHIT Fund. This statement has been made available on the GHIT Fund's fifth anniversary website.
*1. Global Health Innovative Technology Fund
The first of its kind in Japan, the GHIT Fund is a public-private partnership between the Japanese government, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP. Launched in April 2013 with an initial commitment of more than US$100 million and now with capital of US$145 million, the organization taps Japanese research and development (R&D) to fight neglected diseases. GHIT Fund invests and manages a portfolio of development partnerships aimed at neglected diseases that afflict the world's poorest people. GHIT Fund mobilizes Japanese pharmaceutical companies and academic and research organizations to engage in the effort to get new medicines, vaccines, and diagnostic tools to people who need them most, with Japan quickly becoming a game-changer in global health.
*2. Information on global research institutions
Global research institution partners include Medicines for Malaria Venture in the field of malaria treatment, the Global Alliance for TB Drug Development in the field of tuberculosis treatment, and Drugs for Neglected Diseases initiative in the field of treatments for neglected tropical diseases (leishmaniasis and Chagas disease).